A Phase 1 interventional study of Inhaled loxapine and Inhaled placebo in Thorough QT/QTc Study, sponsored by Nova Pneuma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Nova Pneuma Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.
Primary Objective: To assess the maximum effect of Staccato Loxapine on cardiac repolarization (QTc interval duration) at the anticipated maximum clinical dose compared to placebo in healthy volunteers.
Secondary Objective: To assess the QTc versus loxapine concentration relationship following treatment with Staccato Loxapine in healthy volunteers.
Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo
Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo
Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo
Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo
Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo
Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo
Inhaled Staccato Loxapine 10 mg single dose
Also known as: ADASUVE
Inhaled Staccato placebo single dose
Oral moxifloxacin 400 mg
Oral placebo similar in appearance to moxifloxacin 400 mg
Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo
Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times
Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.
QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.
Time frame: 24 hours
Numbers and % of Subjects With QTcI > 450 ms
Numbers and Percents of Subjects with QTcI exceeding 450 ms
Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Numbers and % of Subjects With QTcI > 480 ms
Numbers and Percents of Subjects with QTcI exceeding 480 ms
Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Numbers and % of Subjects With QTcI Change > 30 ms
Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms
Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Numbers and % of Subjects With QTcI Change > 60 ms
Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms
Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)
A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points
Time frame: 1, 1.5, 2, 2.5, 3, 5, 8, 12, and 24 hr
132 subjects were screened.
| Milestone | Treatment Sequence ABC | Treatment Sequence ACB | Treatment Sequence BCA | Treatment Sequence BAC | Treatment Sequence CAB | Treatment Sequence CBA |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 7 | 7 | 8 | 8 | 8 |
| Not completed | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times
| mseconds | Inhaled Loxapine 10 mg vs Placebo Crossover Subjects |
|---|---|
| Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo | 5.418 (3.083 to 7.753) |
QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.
| mseconds | Inhaled Loxapine 10 mg |
|---|---|
| Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers. | 4.238 (2.859 to 5.617) |
Numbers and Percents of Subjects with QTcI exceeding 450 ms
| Participants | Inhaled Loxapine 10 mg | Inhaled Placebo |
|---|---|---|
| Numbers and % of Subjects With QTcI > 450 ms | 1 | 1 |
Numbers and Percents of Subjects with QTcI exceeding 480 ms
| Participants | Inhaled Loxapine 10 mg | Inhaled Placebo |
|---|---|---|
| Numbers and % of Subjects With QTcI > 480 ms | 0 | 0 |
Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms
| Participants | Inhaled Loxapine 10 mg | Inhaled Placebo |
|---|---|---|
| Numbers and % of Subjects With QTcI Change > 30 ms | 1 | 1 |
Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms
| Participants | Inhaled Loxapine 10 mg | Inhaled Placebo |
|---|---|---|
| Numbers and % of Subjects With QTcI Change > 60 ms | 0 | 0 |
A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points
| mseconds | Oral Moxifloxacin vs Placebo Crossover Subjects |
|---|---|
| Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity) | 8.356 (5.825 to 10.877) |
Collected over Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Loxapine 10 mg | 0/47 (0%) | 0/47 (0%) | 38/47 (80.9%) |
| Placebo | 0/47 (0%) | 0/47 (0%) | 19/47 (40.4%) |
| Oral Moxifloxacin | 0/47 (0%) | 0/47 (0%) | 9/47 (19.1%) |
| Event | Inhaled Loxapine 10 mg | Placebo | Oral Moxifloxacin |
|---|---|---|---|
| SomnolenceNervous system disorders | 29/47 | 7/47 | 2/47 |
| DizzinessNervous system disorders | 17/47 | 2/47 | 4/47 |
| DysgeusiaGastrointestinal disorders | 9/47 | 1/47 | 2/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/47 | 2/47 | 1/47 |
| HeadacheNervous system disorders | 2/47 | 4/47 | 2/47 |
| Dermatitis, contactSkin and subcutaneous tissue disorders | 3/47 | 3/47 | 0/47 |
Safety population
| Age, Categorical(Participants) | All Subjects Treated |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 48 |
| >=65 years | 0 |
| Age, Continuous(years) | All Subjects Treated |
|---|---|
| Mean | 40.854 ± 13.481 |
| Sex: Female, Male(Participants) | All Subjects Treated |
|---|---|
| Female | 24 |
| Male | 24 |
| Region of Enrollment(participants) | All Subjects Treated |
|---|---|
| United States | 47 |
Plan to share: Yes — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsDoc@alexza.com
The record gives a start of Apr 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 10 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Loxapine
Nova Pneuma Inc.